Trevena, Inc. (TRVN) |
|
1.66 -0.02 (-1.19%)
|
02-03 15:39 |
|
Open: |
1.68 |
Pre. Close: |
1.68 |
|
High:
|
1.7299 |
Low:
|
1.58 |
|
Volume:
|
157,761 |
Market Cap:
|
13(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 3:21:12 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 2.26  One year: 2.69 |
| Support: |
Support1: 1.33 Support2: 1.1 |
| Resistance: |
Resistance1: 1.93 Resistance2: 2.3 |
| Pivot: |
1.81  |
| Moving Average: |
MA(5): 1.66 MA(20): 1.84
MA(100): 3.13 MA(250): 6.4 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 9.3 %D(3): 9.7 |
| RSI: |
RSI(14): 36.4 |
| 52-week: |
High: 15.27 Low: 0.25 |
| Average Vol(K): |
3-Month: 93 (K) 10-Days: 73 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TRVN ] has closed above bottom band by 16.3%. Bollinger Bands are 56.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.76 - 1.77 |
1.77 - 1.77 |
|
Low:
|
1.62 - 1.63 |
1.63 - 1.65 |
|
Close:
|
1.66 - 1.68 |
1.68 - 1.7 |
|
Company Description |
|
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania. |
Headline News |
Tue, 31 Jan 2023
Humane Society faces increased demand - The Carroll News
Tue, 17 Jan 2023
Is Trevena Inc (TRVN) a Stock to Watch After Gaining 17.98% This Week? - InvestorsObserver
Thu, 12 Jan 2023
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial ... - MyChesCo
Mon, 09 Jan 2023
Trevena Enrolls First Subject in TRV045 Proof-of-Concept Trial ... - GlobeNewswire
Tue, 29 Nov 2022
Trevena Regains Compliance with Nasdaq Listing Requirements - Yahoo Finance
Wed, 16 Nov 2022
Trevena Launches $8 Million Registered Direct Stock Offering; Shares Fall - Marketscreener.com
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
165 (M) |
|
% Held by Insiders
|
1.7142e+008 (%) |
|
% Held by Institutions
|
1.4 (%) |
|
Shares Short
|
3,430 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-5.858e+007 |
|
EPS Est Next Qtl
|
-0.32 |
|
EPS Est This Year
|
-1.37 |
|
EPS Est Next Year
|
-0.94 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-29 |
|
Return on Assets (ttm)
|
500 |
|
Return on Equity (ttm)
|
-41.7 |
|
Qtrly Rev. Growth
|
200000 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
-49.99 |
|
EBITDA (p.s.)
|
-206952 |
|
Qtrly Earnings Growth
|
-0.3 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-54 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.04 |
|
Price to Cash Flow
|
4.63 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
3.22e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
